NVO: Ziltivekimab Fails to Show MACE Risk Reduction
NVO's ziltivekimab misses MACE risk reduction target
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
NVO's ziltivekimab misses MACE risk reduction target
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.